News
Clinical Topics
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Breaking Barriers
Face Off
Morning Rounds
OncView
Podcasts
Readout 360
Sponsored Media
Training Academy
Treatment Algorithms with the Oncology Brothers
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
Satellite Sessions
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Career Center
Subscribe
Choose Specialty
Adverse Effects
Biomarkers
Brain Cancer
Breast Cancer
Breast Cancer
Breast Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Head & Neck Cancer
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hormone-related Cancers
Immunotherapy
Infection
Infection
Leukemia
Lung Cancer
Lung Cancer
Lung Cancer
Lymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Choose Specialty
Adverse Effects
Biomarkers
Brain Cancer
Breast Cancer
Breast Cancer
Breast Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Head & Neck Cancer
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hormone-related Cancers
Immunotherapy
Infection
Infection
Leukemia
Lung Cancer
Lung Cancer
Lung Cancer
Lymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight
News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe
Advertisement
IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications
: Episode 7
CheckMate 9DW: Overview
September 23, 2024
By
Daniel Ahn, DO
Rahul Gosain, MD
Rohit Gosain, MD
View All
Opinion
Video
The panel reviews the CheckMate 9DW study design and evaluates its safety data.
EP: 1.
IMbrave 150: Overview
EP: 2.
IMbrave 150: Patient Characteristics
EP: 3.
IMbrave 150: Updated Outcomes
EP: 4.
Using Atezolizumab + Bevacizumab in Practice
EP: 5.
Vp4 and Baseline Varices Data in IMbrave 150: Clinical Implications
EP: 6.
AE Management with Atezolizumab + Bevacizumab
Now Viewing
EP: 7.
CheckMate 9DW: Overview
EP: 8.
Advanced HCC: Key Takeaways
Recent Videos
Related Content
Related Content
Advertisement